Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews.

Expert Review of Pharmacoeconomics & Outcomes Research
Vakaramoko DiabyAskal Ali

Abstract

Introduction: Treatment of human epithelial growth factor receptor 2 (HER2)-positive breast cancer has rapidly evolved over the past decades with the addition of trastuzumab, lapatinib, pertuzumab, and trastuzumab emtansine (T-DM1). These treatments have dramatically impacted the survival of HER2-positive metastatic breast cancer (mBC) patients. Nonetheless, these agents are associated with high price tags, begging the question, 'Are treatments for HER2-positive metastatic breast cancer and associated metastases cost-effective'?Areas covered: We examine evidence on the cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases through a review of systematic reviews on the topic. Additionally, we discuss the implications of our findings and provide recommendations for future directions in the assessment of the cost-effectiveness of targeted directed agents for HER2-positive mBC.Expert opinion: Heterogeneous evidence from cost-effectiveness studies on the use of targeted directed agents for HER2-positive mBC across the world caution against cross-country comparisons of the value of such treatments. It also militates in favor of the production and use of cost-effectiveness analyses for lo...Continue Reading

References

Apr 11, 2001·Emerging Infectious Diseases·R D ScottJ E McGowan
Jan 22, 2003·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Milton C WeinsteinUNKNOWN ISPOR Task Force on Good Research Practices--Modeling Studies
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elena B ElkinJane C Weeks
Mar 2, 2005·International Journal of Technology Assessment in Health Care·Mattias J NeytVéronique F Cocquyt
Apr 26, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J NorumJ A Olsen
Jul 9, 2008·Acta Oncologica·Mathias LidgrenClas Rehnberg
Oct 11, 2008·American Journal of Clinical Oncology·Bénédicte PoncetVéronique Trillet Lenoir
Jun 3, 2009·American Journal of Clinical Oncology·Carole Perez-EllisAnne-Gaëlle Le Corroller-Soriano
Jul 25, 2009·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Louis P Garrison, David L Veenstra
Feb 9, 2010·Breast Cancer Research and Treatment·Marilyn L KwanLawrence H Kushi
May 7, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K W Matter-WalstraB C Pestalozzi
Feb 5, 2011·BMC Medical Research Methodology·Valerie SmithMike Clarke
Jun 28, 2011·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Thomas E DeleaDavid Cameron
Nov 30, 2011·Nature Reviews. Clinical Oncology·Carlos L ArteagaLuca Gianni
Dec 8, 2011·Chest·Leslie P Scheunemann, Douglas B White
May 7, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sharon H GiordanoUNKNOWN American Society of Clinical Oncology
Nov 11, 2014·Revista de salud pública·Liliana Chicaíza-BecerraCarlos Castañeda-Orjuela
Sep 10, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ben Y DurkeeKathleen C Horst
Nov 6, 2015·Journal of the National Cancer Institute·Jane J KimUNKNOWN Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) consortium
Jul 10, 2017·Breast Cancer Research and Treatment·Xavier Ghislain Léon Victor PouwelsManuela A Joore
Dec 15, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·N A NixonS Verma
Jan 5, 2018·Statistical Methods in Medical Research·Jiaqi LiNandita Mitra
Sep 6, 2018·PharmacoEconomics Open·Vakaramoko DiabyAlberto J Montero
Jan 4, 2019·Breast Cancer Research and Treatment·Anagha GogateStephanie B Wheeler
Dec 6, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jinani Jayasekera, Jeanne S Mandelblatt
Dec 12, 2019·The New England Journal of Medicine·Shanu ModiUNKNOWN DESTINY-Breast01 Investigators
Dec 12, 2019·The New England Journal of Medicine·Rashmi K MurthyEric P Winer
Jul 18, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cristina SauraUNKNOWN NALA Investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Related Papers

The New England Journal of Medicine
Sandra M SwainJosé Baselga
The New England Journal of Medicine
Mette S van Ramshorst, Gabe S Sonke
The New England Journal of Medicine
Tim J A Dekker
The Lancet Oncology
Sridhar Papaiah SusheelaAjaikumar Basavalingaiah
© 2021 Meta ULC. All rights reserved